Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Miners power Footsie gains

Mon, 09th Nov 2009 16:31

Mining stocks were at the vanguard of a strong advance from FTSE 100 as commodity prices were boosted by plans outlined by world leaders over the weekend to continue with stimulus measures.Kazakhmys, Fresnillo, Rio Tinto and Vedanta were some of the best performers in the mining sector.Mining giant Anglo American has added former Sainsbury chairman, Sir Philip Hampton, to the board in a non-executive role. Hampton has been chairman of Royal Bank of Scotland (RBS) since February 2009. After all the waiting and speculation, the formal bid for Cadbury from US group Kraft Foods proved a disappointment.Kraft formally announced a bid for Cadbury on the same terms as the indicative offer announced at the beginning of September. Not surprisingly, the Cadbury board gave the offer short shrift, noting that the terms of 300p cash plus 0.2589 Kraft Foods shares for every Cadbury share actually value each Cadbury share at a lower value now than when the bid terms were first mooted, thanks to the slide in Kraft's share price in the intervening weeks. Cadbury shares initially tumbled from just below 770p to just below 745p on the announcement of the bid terms but later moved back into the blue. The Kraft terms value each Cadbury share at 717p based on Friday's closing share price for Kraft.Prudential went well in a buoyant insurance sector after ING upped its price target for the stock from 392p to 584p.Cash-strapped bank Royal Bank of Scotland is also in demand after week-end analysis of last week's results and government asset protection scheme announcement.Inmarsat was on a high after the satellite operator lifted profits by nearly a third over the past three months. Revenue overall in the three months to September rose by 8.7% to $176.7m (2008: $162.5m). Profit before tax rose by 31% to $70m. Free cash flow rose 6% to $102.9m (2008: $54.0m).Fellow Footsie stock G4S fell, however, after it said things have been steady at the security services firm since August's interims. Operating profit for the first nine months of 2009 was up 25% at actual exchange rates and revenue rose by 23%. At constant exchange rates, profit rose 12% and revenue by 9%.Insurer and reinsurer Beazley has seen strong growth in premiums written this year, even after it pushed through rate increases. Gross premiums written in the first nine months of 2009 rose 45% to £861.9m from £595.4m in the first nine months of last year.Hiscox was in confident mood after boosting premium income by 31.7% in the first nine months of 2009, giving the specialist insurer "good reasons to be optimistic".Sales slumped further at Aer Lingus over the past three months with revenue down by nearly 10% as fares came under heavy pressure both on short-haul and long-haul flights.Oil and gas production levels were both higher in the third quarter at energy company JKX Oil and Gas. Total production in the third quarter of 2009 rose to 13,657 barrels of oil equivalent per day (boepd), up 24% from 10,978 boepd in the same period of 2008.Metal basher IMI has made a thumping gain after saying it expects earnings this year to come in " materially higher" than previously forecast as higher margins have offset a sharp fall in revenues.Shares in online poker giant PartyGaming have come up trumps following the group's purchase of the owner of the World Poker Tour brand. The company has paid £12.3m in cash for WPT Enterprises. Engineering and construction group Costain has been appointed to assist with a roadworks programme in the Midlands arising from the government's fiscal stimulus plan.The share price of respiratory disease drug developer Synairgen more than doubled in early trading on Monday after lab test suggested its inhaled interferon beta product could combat swine flu.FTSE 100 - RisersRoyal Bank of Scotland Group (RBS) 39.40p +6.30%Kazakhmys (KAZ) 1,286.00p +6.02%Prudential (PRU) 608.00p +5.19%Xstrata (XTA) 1,011.00p +5.04%Antofagasta (ANTO) 893.00p +4.63%Vedanta Resources (VED) 2,367.00p +4.60%Inmarsat (ISAT) 621.00p +4.46%Fresnillo (FRES) 875.00p +4.35%Legal & General Group (LGEN) 83.25p +4.32%Rio Tinto (RIO) 3,042.00p +4.29%FTSE 100 - FallersCable & Wireless (CW.) 136.80p -1.58%G4S (GFS) 249.90p -1.15%Next (NXT) 1,967.00p -0.41%WPP Group (WPP) 568.50p +0.09%Severn Trent (SVT) 946.50p +0.11%SEGRO (SGRO) 346.30p +0.14%Capita Group (CPI) 768.50p +0.20%British American Tobacco (BATS) 1,963.00p +0.20%Tesco (TSCO) 418.85p +0.20%British Airways (BAY) 199.30p +0.25%FTSE 250 - RisersIMI (IMI) 529.50p +15.16%Yell Group (YELL) 48.00p +8.72%Punch Taverns (PUB) 93.50p +6.13%Cookson Group (CKSN) 393.60p +5.52%Ferrexpo (FXPO) 168.20p +4.99%Dunelm Group (DNLM) 390.00p +4.64%Bodycote (BOY) 172.50p +4.61%Chloride Group (CHLD) 173.50p +4.58%Talvivaara Mining Company (TALV) 380.30p +4.45%Petropavlovsk (POG) 1,284.00p +4.39%FTSE 250 - FallersForth Ports (FPT) 1,135.00p -4.46%Fidessa (FDSA) 1,217.00p -3.11%Filtrona PLC (FLTR) 174.50p -3.06%Berkeley Group Holdings Units (BKG) 831.00p -2.86%Stobart Group (STOB) 124.50p -2.73%Cranswick (CWK) 680.50p -2.23%Genus (GNS) 634.50p -2.08%Go-Ahead Group (GOG) 1,365.00p -1.87%Avis Europe (AVE) 25.93p -1.78%Morgan Sindall (MGNS) 550.50p -1.70%
More News
14 Mar 2019 14:47

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

Read more
14 Mar 2019 11:37

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

Read more
25 Feb 2019 11:41

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

Read more
22 Oct 2018 11:53

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

Read more
22 Oct 2018 09:20

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

Read more
25 Sep 2018 13:48

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

Read more
15 Mar 2018 12:57

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

Read more
12 Oct 2016 09:52

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

Read more
22 Mar 2016 11:07

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

Read more
21 Mar 2016 16:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Nov 2015 11:35

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

Read more
16 Sep 2015 13:03

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

Read more
16 Sep 2015 09:50

Synairgen Swings To Loss As AstraZeneca Revenue Bump Doesn't Repeat

Read more
5 Aug 2015 10:21

Synairgen shares surge on research collaboration deal

(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea

Read more
5 Aug 2015 07:42

Synairgen Signs Research Collaboration Deal With Australia's Pharmaxis

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.